Objectives Mycoplasma genitalium and Chlamydia trachomatis are the primary pathogens detected from non-gonococcal urethritis (NGU). In this study, the efficacy of gatifloxacin was examined against M genitalium-related urethritis.
Methods The study was an open clinical trial evaluating the effectiveness of gatifloxacin with 200 mg doses twice a day for 7 days against male NGU.
Results Between March and September 2008, 169 male patients were enrolled, and microbiological and clinical cure rates could be evaluated in 86 patients detected with C trachomatis or M genitalium and in 135 with NGU, respectively. Microbiological cure rates of gatifloxacin against C trachomatis and M genitalium were 100% and 83%, respectively, and the total clinical cure rate was 99%.
Conclusion Analysis of in-vivo and in-vitro data from the literature of fluoroquinolone efficacies against M genitalium suggests that a MIC90 of 0.125 μg/ml or less may be useful for optimal activity against M genitalium infection.
- clinical trials
Statistics from Altmetric.com
Funding This study received funding from the Supporting Center for Clinical Research and Education (SCCRE), Osaka, Japan.
Competing interests None declared.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the ethics committee of Osaka University, Osaka, Japan.
Provenance and peer review Not commissioned; externally peer reviewed.